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Background. In vitro studies with isolated arteries have shown direct vasoactivity of racemic bupivacaine. However, there is
little information on the direct vasoactivities of bupivacaine enantiomers, S(−)- and R(+)-bupivacaine. Methods.W ep e r f o r m e d
functional examinations using isolated intact thoracic aortic rings from male Wistar rats. Changes in ring tension produced
by S(−)-, R(+)-, or racemic bupivacaine were measured in Krebs solution. Results.S ( −)-bupivacaine produced the strongest
contraction of the three agents. R(+)-bupivacaine showed limited vasoconstriction. The eﬀects of racemic bupivacaine were
located between these two. Conclusion. Each bupivacaine enantiomer showed speciﬁc vasocontractile activity, which aﬀects the
activity of racemic bupivacaine.
1.Introduction
The local anesthetic bupivacaine is a racemic mixture
of S(−)- and R(+)-enantiomers. Racemic bupivacaine has
biphasic vasoactivities, namely, vasoconstriction at a low
concentration and vasodilatation at a high concentration
[1]. Since 1976, when Aps and Reynolds showed this
vasoactivity in a double-blind trial with forearm skin color
changes of 31 volunteers [1], these vasoactivities have been
further demonstrated using various in vivo methods with
various animals or humans, such as television microscopy
in rat cremaster muscle microvasculatures [2], intravital
microscopythroughaspinalwindowindogpialvasculatures
[3], laser Doppler imaging in human skin [4], as well
as other techniques. Although inhibition of sympathetic
nerves innervating arteries by racemic bupivacaine could
not be ignored in in vivo studies, some in vitro studies
withisolatedpreparationsfromhumanumbilicalarteries[5–
7], rat uterine arteries [8], and human uterine arteries [9]
have conﬁrmed that the vasoactivities are produced by direct
actions of racemic bupivacaine itself on the arteries.
S(−)-bupivacaine was developed as an alternative long-
acting local anesthetic with a clinical proﬁle similar to
that of racemic bupivacaine but with a lower potential
for producing systemic toxicity [10]. S(−)-bupivacaine also
has biphasic vasoactivities similar to those of racemic
bupivacaine, which has been shown in in vivo studies [4,
11–13]. Furthermore, some of the in vivo studies have
shown that R(+)-bupivacaine produced a dose-dependent
vasodilatation [11, 13]. However, there is little information
on the direct vasoactivities of S(−)- and R(+)-bupivacaine
based on in vitro study. In this study, we investigated the
vasocontractile activities of these agents using isolated rat
aorta.
2. Methods
2.1. Animals. The experimental protocol was approved by
the institutional animal care committee of Asahi University.
Male Wistar rats weighing 240–280g were used.
2.2. FunctionalExperiments. Rats were killed by decapitation
under sevoﬂurane anesthesia, and the thoracic aorta was
isolated and removed [14]. The thoracic aorta was placed in
Krebs-Henseleit solution (mM; NaCl 118, KCl 4.7, NaHCO3
25, KH2PO4 1.2, MgSO4 1.2, CaCl2 2.5, and glucose 10; pH
7.4). Aortic rings were carefully prepared under a dissecting
microscope, and then each intact ring was carefully pulled by
wires in an organ chamber containing 5mL Krebs-Henseleit2 Anesthesiology Research and Practice
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Figure 1: Changes in vascular tension provoked by S(−)-, R(+)-,
and racemic bupivacaines.
∗: P<. 05 versus R(+)-bupivacaine.
n = 8.
solution bubbled with 95% O2 and 5% CO2 at 37◦C. After
a resting tension of 1.0g was applied during one-hour
equilibration period, changes in the tension were recorded
isometrically when S(−)-bupivacaine, R(+)-bupivacaine, or
racemic bupivacaine was cumulatively applied. Contractions
were expressed as mg contractile tension.
2.3. Chemicals. S(−)-bupivacaine and R(+)-bupivacaine
were generously donated by Maruishi Pharmaceutical
(Osaka, Japan), and pseudoracemic bupivacaine was
prepared by mixing with S(−)-bupivacaine and R(+)-
bupivacaine at a ratio of 1 : 1 [15].
2.4. Statistical Analysis. The results are expressed as mean ±
SD. The maximum response (Emax) and the concentration
producing a half-maximal response (EC50) were determined
by Finley’s probit analysis. Signiﬁcance of diﬀerences was
analyzed by Kruskal-Wallis test and Scheﬀ´ e method as a post
hoc comparison for multiple comparisons at a signiﬁcance
level of 0.05.
3. Results
S(−)-bupivacaine, R(+)-bupivacaine, and racemic bupiva-
caine produced a biphasic response in the aortic rings,
namely, concentration-dependent contraction from 10μM
to 1mM and relaxation at higher concentrations (n = 8,
Figure 1.) The vasocontractile responses produced by S(−)-
bupivacaine and racemic bupivacaine were signiﬁcantly
stronger than those by R(+)-bupivacaine. Furthermore,
thereweresigniﬁcantdiﬀerencesamongEmax orEC50 ofeach
bupivacaine (Table 1).
Table 1: EC50 values and maximum contraction by bupivacaines.
Bupivacaine EC50(×10
−5)E max (g)
S( −)7 . 3 ± 2.9 0.31 ± 0.06
R( + ) 4 . 1± 4.0∗ 0.12 ± 0.10∗
Racemic 4.1 ± 1.6∗ 0.21 ± 0.10
∗ P<. 05 versus S(−). n = 8.
4. Discussion
As there has been only limited study of the direct vasoac-
tivities of two bupivacaine enantiomers, S(−)- and R(+)-
bupivacaine, we compared the vasocontractile eﬀects of
these two agents with that of racemic bupivacaine in
this study. S(−)-bupivacaine showed the strongest Emax of
the three agents, while R(+)-bupivacaine showed limited
vasoconstriction. Although racemic bupivacaine produced
as much Emax as S(−)-bupivacaine statistically (Table 1), the
activity level of racemic bupivacaine was located between
those of S(−)-bupivacaine and R(+)-bupivacaine graphi-
cally (Figure 1). R(+)-bupivacaine, which produced small
vasoconstriction even at high concentration, may interfere
with vasoconstriction by S(−)-bupivacaine in racemic bupi-
vacaine, which consists of the two enantiomers. Several in
vitro studies have been done on racemic bupivacaine’s direct
vasoactivities. It has been reported that racemic bupivacaine
contracted isolated rat uterine arteries [8], human uterine
arteries [9], human umbilical arteries [5–7], and veins [6]
in various degrees. Diﬀerent vasocontractile activities of the
enantiomers among the vessels might be, at least, a cause of
the variety.
S(−)-bupivacaine produced the strongest vasoconstric-
tion of the three bupivacaines in our study. Considering
that the clinical use of S(−)-bupivacaine is increasing
because of its lower toxicity [10], it is important to note
that it may produce greater vasoconstriction than racemic
bupivacaine does. Bupivacaine administered for epidural
anesthesia raises the intrathecal and plasma concentration
[16] and might contract several important vessels, including
the pial, epidural, uterine, umbilical arteries, as well as
others, with subsequent decrease of blood ﬂow.
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